Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Executive Summary
Pfizer is launching its second US biosimilar, a version of filgrastim, at an aggressive 30.3% discount to Amgen's branded Neupogen and at a discount to competing biosimilars.
You may also be interested in...
10 Things For Pfizer's New CEO To Worry About
Albert Bourla will face opportunities and potential pitfalls.
Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label
Oncologic Drugs Advisory Committee says totality of evidence supports licensure of CT-P10 for three lymphoma indications, but panelists question what additional data would be needed to eventually get Rituxan’s other approved uses, which were carved out for patent and exclusivity reasons, onto the biosimilar’s label.
Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label
Oncologic Drugs Advisory Committee says totality of evidence supports licensure of CT-P10 for three lymphoma indications, but panelists question what additional data would be needed to eventually get Rituxan’s other approved uses, which were carved out for patent and exclusivity reasons, onto the biosimilar’s label.